In the last year we have begun to study purified PN to establish its physiological functions and possible relationship to cancer. Studies of its kinetics of inhibition by various serine proteases demonstrate that PN is a broad specificity inhibitor of arginyl- or lysyl-specific serine proteases. Thus, PN inhibits bovine trypsin with an association rate constant of 2 X 10?6? M?-1? S?-1?, thrombin (4 x 10?5? M?-1? S?-1?), urokinase (2 x 10?5? M?-1? S?-1?), plasmin (2 x 10?5? M?-1? S?-1?), two chain tissue-type plasminogen activator (1 x 10?4? M?-1? S?-1?), Factor Xa (3 x 10?3? M?-1? S?-1?), NGF gamma subunit (2 x 10?3? M?-1? S?-1?), and single chain tissue-type plasminogen activator (2 x 10?3? M?-1? S?-1?). These results indicate that PN inhibits a variety of plasminogen activators and other fibrinolytic proteases. The breadth of specificity of PN suggests that the nature of the key physiologic target proteases may be determined by propinquity. We are currently examining the interaction of fibroblast PN with tryptase, a lys/arg-specific serine protease that is present in human dermis. Studies on the mechanism of regulation of plasminogen activator by human fibrosarcoma (HT1080) cells are nearing completion. These cells have been found to be like normal human fibroblasts in that they release plasminogen activator only in a latent form (urokinase proenzyme) and also release PN. However, these cells differ from normal fibroblasts in that they release vastly elevated amounts of the urokinase proenzyme and depressed amounts of PN. When HT1080 cells are grown on extracellular matrix (ECM) produced by smooth muscle cells they, unlike normal fibroblasts, degrade the matrix at a rapid rate. The ECM degradation is inhibited by about 50% by anti-urokinase antibody and is plasminogen-dependent, indicating that it involves cell plasminogen activator activity. Purified PN at a 20nm concentration completely inhibits the ECM degradation for several days. However, thereafter the cells degrade the ECM at a rapid rate. Purified PN at 0i2 mu-M concentration completely inhibits the ECM degradation for the entire 10-day duration of the experiment. The inhibition of matrix degradation is accompanied by an inhibition of HTI080 cell proliferation on the ECMs. PN does not affect the proliferation of normal fibroblasts. (B)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA029307-05
Application #
3168644
Study Section
Cognition and Perception Study Section (CP)
Project Start
1980-12-01
Project End
1986-11-30
Budget Start
1984-12-01
Budget End
1985-11-30
Support Year
5
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Kansas Lawrence
Department
Type
Schools of Arts and Sciences
DUNS #
072933393
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Gronke, R S; Knauer, D J; Veeraraghavan, S et al. (1989) A form of protease nexin I is expressed on the platelet surface during platelet activation. Blood 73:472-8
Hebert, C A; Baker, J B (1988) Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J Cell Biol 106:1241-7
Van Nostrand, W E; McKay, L D; Baker, J B et al. (1988) Functional and structural similarities between protease nexin I and C1 inhibitor. J Biol Chem 263:3979-83
Gronke, R S; Bergman, B L; Baker, J B (1987) Thrombin interaction with platelets. Influence of a platelet protease nexin. J Biol Chem 262:3030-6
Gronke, R S; Curry, T K; Baker, J B (1986) Formation of protease nexin-thrombin complexes on the platelet surface. J Cell Biochem 32:201-6
Baker, J B; Gronke, R S (1986) Protease nexins and cellular regulation. Semin Thromb Hemost 12:216-20
Scott, R W; Bergman, B L; Bajpai, A et al. (1985) Protease nexin. Properties and a modified purification procedure. J Biol Chem 260:7029-34